PGS2 A RETROSPECTIVE AUDIT OF PATIENTS REDUCING PROTON PUMP INHIBITOR DOSE TO LANSOPRAZOLE 15MG  by Emmas, CE & Rosen, JP
683Abstracts
DIABETES—Quality of Life Studies
PDB20
THE IMPACT OF DIABETES TYPE 2 ON
QUALITY OF LIFE
Niewada MP1, Glogowski CA2, Gierczynski JM2, Latek M3,
Pietrasik AL1, Kamiñski B3, Krzyzanowska AM2
1Medical University of Warsaw, Warsaw, Poland;
2GlaxoSmithKline Pharmaceuticals S.A, Warsaw, Poland;
3Warsaw School of Economics, Warsaw, Poland
OBJECTIVES: The Cost Of Diabetes type 2 in Poland
(CODIP) study is the ﬁrst attempt aimed at valuating clin-
ical characteristics and Health Related Quality of Life
(HRQoL) associated with type 2 diabetes in Poland.
METHODS: We assessed quality of life of 303 patients
(mean age 61, mean time from diagnosis 10,86 year,
males 49%). Detailed information on quality of life was
collected with EuroQol-5D and Visual Analog Scale. The
inﬂuence of complications and therapeutic strategies on
quality of life was evaluated. The HRQoL score was ana-
lyzed as a function of number and type of complications
or therapeutic strategies, controlled for age, BMI and sex.
RESULTS: The strong relationship between HRQoL and
complications was observed. Patients without com-
plications reported mean HRQoL of 0.63 (95% CI:
0.59–0.68). The presence of microvascular or macrovas-
cular complications resulted in degresion of HRQoL to
0.55 (95% CI: 0.51–0.59) and 0.53 (95% CI: 0.49–0.58),
respectively. Both types of complications were associated
with the lowest HRQoL value: 0.44 (95% CI: 0.41–0.48).
Patients treated with diet and exercise only reported
quality of life equaled 0.61 (95% CI: 0.47–0.72), while
oral hypoglycemic drugs therapy decreased quality of life
to 0.57 (95% CI: 0.53–0.62). Insulin based therapy was
associated with the lowest quality of life scores: 0.46
(95% CI: 0.41–0.49) for monotherapy to 0.51 (95% CI:
0.47–0.54) for combined use of insulin and oral drugs.
The complications, but not treatment type, were found 
in multivariate analysis to be independent predictor of
HRQoL. CONCLUSIONS: Patients diabetes type 2’s
quality of life is affected by complications. Prevention of
complications may result in signiﬁcant improvement of





AN EVIDENCE-BASED APPROACH PROVIDES 
A QUANTITATIVE ASSESSMENT OF THE
EFFICACY OF ESOMEPRAZOLE FOR HEALING
OF EROSIVE ESOPHAGITIS BASED ON DISEASE
SEVERITY
Johnson DA1, Roach A2,Traxler BM2, Levine D2
1Eastern Virginia School of Medicine, Norfolk,VA, USA;
2AstraZeneca LP, Wilmington, DE, USA
OBJECTIVE: Number needed to treat (NNT) provides
an estimate of the number of patients who need to be
treated with a drug to avoid an adverse outcome on alter-
nate therapy. This quantitative analysis focused on treat-
ment responses to proton pump inhibitors according 
to disease severity. METHODS: Efﬁcacy data from four
clinical trials using once-daily esomeprazole 40mg com-
pared with omeprazole 20mg (n = 3) and lansoprazole
30mg (n = 1) for treatment of erosive esophagitis (EE)
were identiﬁed. EE was graded A–D using the Los Angeles
(LA) classiﬁcation. For each trial we calculated the ther-
apeutic gain, the absolute risk reduction (ARR) and the
number needed to treat (NNT) for healing EE at week 8,
for all patients (LA Grades A–D) and separately for those
with severe disease (LA Grades C & D). RESULTS: For
all grades of esophagitis, the therapeutic gain achieved
with esomeprazole was 9.5%, 7.2% and 2.4% versus
omeprazole, and 3.8% versus lansoprazole. The NNT
with esomeprazole for severe disease ranged between 5
and 10 relative to omeprazole. The NNT with esomepra-
zole for severe disease was 8 relative to lansoprazole, indi-
cating that for every 8 patients treated with esomeprazole,
1 treatment failure with lansoprazole may be prevented.
CONCLUSIONS: Treatment with esomeprazole pro-
vided therapeutic gain regardless of the baseline severity
of EE compared with lansoprazole and omeprazole.
Because the severity of clinical symptoms is not predic-
tive of disease severity, treatment with the most effective
agent appears to be a rational therapeutic decision as sup-
ported in this evidence-based approach.
PGS2
A RETROSPECTIVE AUDIT OF PATIENTS
REDUCING PROTON PUMP INHIBITOR DOSE
TO LANSOPRAZOLE 15MG
Emmas CE, Rosen JP
AstraZeneca UK, Luton, United Kingdom
OBJECTIVES: NICE recommends the use of proton
pump inhibitors (PPIs) at the lowest effective dose in
patients with gastroesophageal reﬂux disease. Changing
patients from a standard or high dose PPI to esomepra-
zole 20mg has shown that only 5% (8/146) of patients
returned to a higher dose PPI in the subsequent 6 months.
The purpose of this study was to assess the frequency with
which patients who had reduced PPI dose to lansoprazole
15mg returned to a higher dose PPI. METHODS: A ret-
rospective audit of electronic patient records at 4 UK
general practices identiﬁed patients on continuous PPI
therapy at standard or high dose who had been switched
to lansoprazole 15mg and recorded any changes in PPI
therapy during the subsequent 6 months. RESULTS: The
audit identiﬁed 175 patients previously on regular (≥2 PPI
prescriptions in the previous 6 months) standard or high
dose PPI who had been changed to lansoprazole 15mg.
Within 6 months of the ﬁrst lansoprazole 15mg pre-
scription, 26% (46/175) of patients had changed back to
a higher dose PPI. Similar switch rates were obtained if
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the analysis was restricted to patients who had received
≥4 prescriptions in the 6 months prior to their ﬁrst lan-
soprazole 15mg prescription (25%: 31/122). Amongst
those patients with a speciﬁc diagnosis of GORD/RO,
37% (15/41) switched to a higher dose PPI within 6
months. Around half (52%; 16/31) of patients who
returned to a higher dose had no speciﬁc reason recorded
(16/31). However the most commonly recorded reason
for failing on lansoprazole 15mg was inadequate control
of symptoms (35%; 11/31). CONCLUSION: The pro-
portion of patients changed from standard or high dose
PPI to lansoprazole 15mg who required an increase in
PPI therapy within 6 months was higher than that re-
ported for patients treated with esomeprazole 20mg.
PGS3
META-ANALYSIS OF PPI-BASED TRIPLE
THERAPY FOR THE ERADICATION OF
HELICOBACTER PYLORI
Edwards SJ, Plumb JM
AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom
OBJECTIVE: The recommended treatment for Heli-
cobacter pylori eradication in the UK is a proton pump
inhibitor (PPI) in combination with amoxicillin 1g and
clarithromycin 500mg all twice daily for 7 days. The aim
of this analysis was to compare the efﬁcacies of the rec-
ommended PPI-based triple therapies for the eradication
of H. pylori using omeprazole-based triple therapy as a
common comparator. METHODS: The PPIs licensed in
the UK for twice daily triple therapy are esomeprazole 
20mg (EAC), lansoprazole 30mg (LAC), omeprazole 
20mg (OAC), pantoprazole 40mg (PAC), and rabepra-
zole 20mg (RAC). A meta-analysis of randomised con-
trolled trials comparing a 7-day regimen of PPI-based
triple therapies was conducted using omeprazole-based
triple therapy as a common comparator. Data on eradi-
cation rates were extracted and re-analysed, where
required, to provide “intention-to-treat” results. The
primary method of calculating the summary effect esti-
mates used a Fixed Effects model. A chi-squared test was
used to assess heterogeneity for each comparison. A sec-
ondary analysis comparing 7-day regimens of PPI plus
any dose of amoxycillin and clarithromycin was con-
ducted to test the robustness of the results. RESULTS:
The alternative strategies, compared with OAC, provided
the following results—EAC (Relative Risk 1.01; 95%
Conﬁdence Interval: 0.95 to 1.08), LAC (RR 1.05; 95%
CI: 0.94 to 1.17), PAC (RR 0.92; 95% CI: 0.80 to 1.06).
No trials comparing rabeprazole with omeprazole using
UK recommended triple therapy were found. Signiﬁcant
heterogeneity was detected in the LAC comparison with
OAC and so these results should be treated with caution.
The secondary analysis conﬁrmed that there was no sig-
niﬁcant difference in the four alternative strategies 
compared to OAC. CONCLUSIONS: No PPI-based
triple therapy was found to be signiﬁcantly more efﬁca-
cious than omeprazole-based triple therapy. However,
esomeprazole 20mg is the only PPI licensed in the UK for
triple therapy that would be considered a low dose.
PGS4
ESOMEPRAZOLE AS MAINTENANCE THERAPY
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ASSESSMENT OF EFFICACY USING AN
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OBJECTIVE: Evidence-based techniques were applied to
clinical trial data of esomeprazole for maintaining healed
erosive esophagitis (EE) to provide a practical, quantita-
tive analysis of its efﬁcacy relative to lansoprazole.
METHODS: Patients with a history of heartburn and EE,
Los Angeles Grade A–D at baseline, received esomepra-
zole 40mg once daily for up to 8 weeks for healing. Those
with healed EE were randomized to receive once daily
esomeprazole 20mg (n = 615) or lansoprazole 15mg 
(n = 609) for up to 6 months. For this retrospective analy-
sis, the number needed to treat (NNT), the reciprocal of
the absolute risk reduction (ARR), was calculated at 6
months for all patients and for subgroups with mild
disease (LA Grade A or B) and severe disease (LA Grade
C or D). RESULTS: In this evidence-based analysis, it 
was determined that 11 patients with EE would need to
be treated with esomeprazole to prevent one treatment
failure that otherwise may occur with lansoprazole
regardless of the baseline grade of EE. As the severity of
disease increased (LA Grade C or D), the NNT to prevent
one relapse that may otherwise have occurred with lan-
soprazole decreased to 6. CONCLUSIONS: For patients
with more severe disease, the NNT was lower, indicating
a greater likelihood of therapeutic success with esome-
prazole versus lansoprazole. This evidence supports
esomeprazole as an effective treatment for maintenance
of remission and prevention of treatment failure in gas-
troesophageal reﬂux disease patients with EE.
GASTROINTESTINAL DISORDERS—Cost Studies
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